Check Cap (NASDAQ:CHEK) had its price target raised by investment analysts at HC Wainwright from $5.50 to $6.00 in a report issued on Thursday. The firm currently has a “buy” rating on the medical research company’s stock.

Other research analysts also recently issued research reports about the company. Maxim Group restated a “buy” rating and issued a $5.00 target price on shares of Check Cap in a research note on Wednesday, September 27th. Zacks Investment Research downgraded Check Cap from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Check Cap currently has a consensus rating of “Hold” and a consensus price target of $4.75.

Check Cap (NASDAQ:CHEK) opened at $0.85 on Thursday. Check Cap has a 12 month low of $0.80 and a 12 month high of $2.55. The company has a market capitalization of $14.44 and a PE ratio of -1.39.

A hedge fund recently raised its stake in Check Cap stock. Sabby Management LLC grew its holdings in shares of Check Cap Ltd (NASDAQ:CHEK) by 467.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,418,893 shares of the medical research company’s stock after acquiring an additional 1,169,061 shares during the quarter. Check Cap comprises 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 24th largest position. Sabby Management LLC owned about 8.36% of Check Cap worth $2,724,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 18.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at

About Check Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.